Reading the tape
AMEX: MAIA
MAIA Biotechnology, Inc.
Healthcare · Biotechnology
Market Cap
$53.74M
52w High
$3.19
52w Low
$0.87
P/E
-1.99
Volume
409.48K
Outstanding Shares
38.66M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -27.23%FCF (TTM): -20%
What changed
The stock fell 27.23% over the last year. Free cash flow declined 20% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 20% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer.
CEOVlad Vitoc
SectorHealthcare
IndustryBiotechnology
Employees13
IPO dateJul 28, 2022
Valuation
Forward P/E—
EV/EBITDA354.72
Enterprise value-$8.61B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-942.65%▼47.33%vs FY2024
Analyst consensus
Rating—
Target price—
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 8, 2026
Q2 FY26 · EPS est -$0.18 · Revenue est —
View